One year in review 2018: novelties in the treatment of rheumatoid arthritis

被引：1

作者：

Bortoluzzi, A. ^{[1
]}

Furini, F. ^{[1
]}

Generali, E. ^{[2
]}

Silvagni, E. ^{[1
]}

Luciano, N. ^{[3
]}

Scire, C. A. ^{[1
,4
]}

机构：

[1] Univ Ferrara, Rheumatol Unit, Dept Med Sci, Ferrara, Italy

[2] Humanitas Clin & Res Ctr, Div Rheumatol & Clin Immunol, Milan, Italy

[3] Univ Pisa, Rheumatol Unit, Dept Clin & Expt Med, Pisa, Italy

[4] Italian Soc Rheumatol, Epidemiol Unit, Milan, Italy

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2018年 / 36卷 / 03期

关键词：

rheumatoid arthritis; biologics; treatment; management; TUMOR-NECROSIS-FACTOR; MODIFYING ANTIRHEUMATIC DRUGS; LONG-TERM EFFECTIVENESS; RANDOMIZED PHASE IIB; LOW DISEASE-ACTIVITY; DOUBLE-BLIND; OPEN-LABEL; MONOCLONAL-ANTIBODY; CLINICAL-OUTCOMES; INADEQUATE RESPONSE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The current approach to treatment of rheumatoid arthritis (RA) includes early and aggressive intervention aiming to reach early and persistent low disease activity and remission. New drugs have improved the therapeutic armamentarium of rheumatologists, providing new options for patients. Beyond these innovations, new evidence has improved the safety of therapies and provided tools for the optimisation of long-term management of RA. This paper reviews the most relevant studies published over the last year in the field of treatment of RA.

引用

下载

页码：347 / 361

页数：15

共 50 条

[31] How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol
Vicenç Torrente-Segarra
Manuel Fernandez Prada
Rosa Expósito Moliner
Noemí Patricia Garrido Puñal
Amalia Sánchez-Andrade Fernández
José Ramón Lamua Riazuelo
Alejandro Olivé
Juan Víctor Tovar Beltrán
Rheumatology International, 2019, 39 : 395 - 398
[32] One year community-based experience with leflunomide in the treatment of rheumatoid arthritis.
Miller, ML
Morton, GL
Anderson, LG
Keroack, BJ
Radis, CD
ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S343 - S343
[33] One year community-based experience with etanercept in the treatment of rheumatoid arthritis.
Miller, ML
Morton, GL
Anderson, LG
Keroack, BJ
Radis, CD
ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S229 - S229
[34] TREATMENT OF RHEUMATOID-ARTHRITIS IN THE YEAR 2000
SCHMIDT, KL
INTERNIST, 1993, 34 (09): : 831 - 840
[35] A review of sarilumab for the treatment of rheumatoid arthritis
Lee, Eun Bong
IMMUNOTHERAPY, 2018, 10 (01) : 57 - 65
[36] Review of tocilizumab in the treatment of rheumatoid arthritis
Okuda, Yasuaki
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 75 - 82
[37] Abatacept for the treatment of rheumatoid arthritis: A review
Kaine, Jeffrey L.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2007, 68 (06): : 379 - 399
[38] 2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis
Tian, Xinping
Wang, Qian
Li, Mengtao
Zhao, Yan
Zhang, Zhiyi
Huang, Cibo
Liu, Yi
Xu, Huji
Chen, Yaolong
Wu, Lijun
Su, Yin
Xiao, Weiguo
Zhang, Miaojia
Zhao, Dongbao
Sun, Linyun
Zuo, Xiaoxia
Lei, Junqiang
Li, Xiaofeng
Zeng, Xiaofeng
RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2021, 2 (01): : 1 - 14
[39] 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis
Lau, Chak Sing
Chia, Faith
Dans, Leonila
Harrison, Andrew
Hsieh, Tsu Yi
Jain, Rahul
Jung, Seung Min
Kishimoto, Mitsumasa
Kumar, Ashok
Leong, Khai Pang
Li, Zhanguo
Lichauco, Juan Javier
Louthrenoo, Worawit
Luo, Shue Fen
Mu, Rong
Nash, Peter
Ng, Chin Teck
Suryana, Bagus
Wijaya, Linda Kurniaty
Yeap, Swan Sim
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (03) : 357 - 375
[40] Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018
Bartoli, Francesca
Bae, Sangmee
Cometi, Laura
Cerinic, Marco Matucci
Furst, Daniel E.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (07) : 539 - 547

← 1 2 3 4 5 →